Predictors of reverse cardiac remodeling after sacubitril/valsartan in heart failure with reduced ejection fraction.

When stratified by average daily Sac/Val dose: <100 mg/day, 100–199 mg/day, and ≥ 200 mg/day, there was an increasing trend in the achievement of reverse cardiac remodeling from patients on lower doses of Sac/Val to those on high doses of Sac/Val (29.5% vs. 32.6% vs. 44.0%; P for trend = 0.046).

also in 63,971 other papers